Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
نویسندگان
چکیده
INTRODUCTION In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA. METHODS Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012.
منابع مشابه
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
OBJECTIVES We assessed the impact of tocilizumab (TCZ), a humanised monoclonal anti-interleukin-6 receptor antibody, on antibody response following administration of the 23-valent pneumococcal polysaccharide vaccine (PPV23). METHODS A total of 190 patients with rheumatoid arthritis (RA) received PPV23. Patients were classified into TCZ (n=50), TCZ + methotrexate (MTX) (n=54), MTX (n=62) and R...
متن کاملOpsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
Vaccination against Streptococcus pneumoniae is recommended for rheumatoid arthritis (RA) patients receiving immunosuppressive treatments. The objective of this study was to evaluate the humoral response to 23-valent pneumococcal polysaccharide vaccination (PPSV23) in RA patients receiving methotrexate (MTX) alone or in combination with a tumor necrosis factor inhibitor, golimumab (GOM).PPSV23 ...
متن کاملPneumococcal vaccine in patients with rheumatoid arthritis.
We read with interest the article by López Garrido et al. on vaccines and chemoprophylaxis in patients with rheumatoid arthritis (RA). In it the authors present a vaccination schedule that included the 23-valent pneumococcal polysaccharide vaccine with booster shots every 3–5 years.1 RA patients are treated with immunosuppressive drugs and this fact determines that such persons are already incl...
متن کاملAntibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
BACKGROUND Patients with rheumatoid arthritis (RA), including those treated with biologics, are at increased risk of some vaccine-preventable infections. We evaluated the antibody response to standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) and the 2011-2012 trivalent seasonal influenza vaccine in adults with RA receiving subcutaneous (SC) abatacept and background disease-modifyi...
متن کاملCONCISE REPORT Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
Department of Rheumatology, Clinical Research Center for Rheumatic Disease, NHO Kumamoto Saishunsou National Hospital, Kohshi, Kumamoto, Japan Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan Oribe Rheumachika-Naika Clinic, Oita, Oita, Japan Department of Internal Medicine, Tomis...
متن کامل